Chenxi Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenxi Sun has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chengyun Zheng
Department of Hematology, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China
2 shared publications - Binggen Li
R&D Department Weihai Zhengsheng Biotechnology Co., Ltd Weihai China
1 shared publication - Chenliu Fan
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication - Dexiao Kong
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication - Huixian Chen
Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China
1 shared publication - Liyuan Liu
Department of Hematology The Second Hospital of Shandong University Jinan Shandong China
1 shared publication
Latest Publications
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70024
PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells
The role of programmed cell death 4 (PDCD4) in multiple myeloma (MM) development remains unknown. Here, we investigated its role and action mechanism in MM. Bioinformatic analysis indicated that patients with MM and high PDCD4 expression had higher overall survival than those with low PDCD4 expression. PDCD4 expression promoted MM cell apoptosis and inhibited their viability in vitro and tumor growth in vivo. RNA‐binding protein immunoprecipitation sequencing analysis showed that PDCD4 is bound to the 5′ UTR of the apoptosis‐related genes PIK3CB , Cathepsin Z ( CTSZ ), and X‐chromosome‐linked apoptosis inhibitor ( XIAP ). PDCD4 knockdown reduced the cell apoptosis rate, which was rescued by adding PIK3CB, CTSZ, or XIAP inhibitors. Dual luciferase reporter assays confirmed the internal ribosome entry site (IRES) activity of the 5′ UTRs of PIK3CB and CTSZ . An RNA pull‐down assay confirmed binding of the 5′ UTR of PIK3CB and CTSZ to PDCD4, identifying the specific binding fragments. PDCD4 is expected to promote MM cell apoptosis by binding to the IRES domain in the 5′ UTR of PIK3CB and CTSZ and inhibiting their translation. Our findings suggest that PDCD4 plays an important role in MM development by regulating the expression of P IK3CB , CTSZ, and XIAP , and highlight new potential molecular targets for MM treatment.
- 27 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (16) , e70024
PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells
The role of programmed cell death 4 (PDCD4) in multiple myeloma (MM) development remains unknown. Here, we investigated its role and action mechanism in MM. Bioinformatic analysis indicated that patients with MM and high PDCD4 expression had higher overall survival than those with low PDCD4 expression. PDCD4 expression promoted MM cell apoptosis and inhibited their viability in vitro and tumor growth in vivo. RNA‐binding protein immunoprecipitation sequencing analysis showed that PDCD4 is bound to the 5′ UTR of the apoptosis‐related genes PIK3CB , Cathepsin Z ( CTSZ ), and X‐chromosome‐linked apoptosis inhibitor ( XIAP ). PDCD4 knockdown reduced the cell apoptosis rate, which was rescued by adding PIK3CB, CTSZ, or XIAP inhibitors. Dual luciferase reporter assays confirmed the internal ribosome entry site (IRES) activity of the 5′ UTRs of PIK3CB and CTSZ . An RNA pull‐down assay confirmed binding of the 5′ UTR of PIK3CB and CTSZ to PDCD4, identifying the specific binding fragments. PDCD4 is expected to promote MM cell apoptosis by binding to the IRES domain in the 5′ UTR of PIK3CB and CTSZ and inhibiting their translation. Our findings suggest that PDCD4 plays an important role in MM development by regulating the expression of P IK3CB , CTSZ, and XIAP , and highlight new potential molecular targets for MM treatment.
- Open Access
- 9 March 2023
- Published by Taylor & Francis in Hematology
- Vol. 28 (1) , 2181749
Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2. Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy. Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.
- 9 March 2023
- Published by Taylor & Francis in Hematology
- Vol. 28 (1) , 2181749
Open AccessSafety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2. Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy. Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.